Etoposide (VP-16-213) plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer
Authors:
- 1 June 1987
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 27 (2) , 233-240
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- CHAP II therapy for epithelial ovarian cancers following primary treatment with platinum-based combination chemotherapyGynecologic Oncology, 1986
- Treatment of persistent or recurrent ovarian carcinoma with sequential methotrexate and 5-fluorouracilGynecologic Oncology, 1986
- Circadian Timing of Cancer ChemotherapyScience, 1985
- Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdensCancer, 1983
- Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation)American Journal of Obstetrics and Gynecology, 1983
- Etoposide single-agent chemotherapy for solid tumorsCancer Treatment Reviews, 1982
- Treatment of chemotherapy-resistant advanced ovarian cancer with a combination of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (CHAP)Gynecologic Oncology, 1981
- Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agentsGynecologic Oncology, 1978
- A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213Cancer, 1975
- Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia—Haematosarcoma and Solid TumoursBMJ, 1973